Burden of testicular, paratesticular and extragonadal germ cell tumours in Europe
Burden of testicular, paratesticular and extragonadal germ cell tumours in Europe
复制标题
DOI：
10.1016/j.ejca.2011.08.020
复制
发表时间：
2012-01-01
影响因子：
8.4
通讯作者：
Berrino，F.
中科院分区：
文献类型：
--
作者：
Trama，A.;Mallone，S.;Berrino，F.
我们提供了欧洲睾丸/睾丸旁和性腺外生殖细胞癌患者的生存率，发病率，完全患病率和治愈比例的最新估计，根据RARECARE制定的新癌症类型列表进行分组。我们收集了数据，在欧洲癌症登记处存档，并提供了截至2003年12月31日的生命状态信息。我们分析了1995-2002年诊断的26，000例睾丸、睾丸旁和性腺外生殖细胞癌，估计欧盟27国每年约有15，600例新发睾丸/睾丸旁和630例新发性腺外生殖细胞癌，年发病率分别为31.5/1，000，000和1.27/1，000，000。2008年初，有436 000多人被诊断为睾丸/睾丸旁癌，约17 000人被诊断为性腺外生殖细胞癌。睾丸/睾丸旁癌和性腺外生殖细胞癌的5年相对生存率分别为96%和71%;治愈率分别为95%和69%。我们发现，欧洲地区之间的生存率差异有限，但非腺瘤性睾丸癌除外，其5年相对生存率从东欧的86%到北方欧洲的96%不等。所有癌症类型的生存率均随着诊断时年龄的增加而下降。需要进一步调查，以确定东欧存活率较低的真实的原因。考虑到这些高度可治愈的癌症的高患病率，重要的是要长期监测患者，以便量化治疗相关风险并开发对生活质量影响有限的治疗方法。
We provide updated estimates of survival, incidence, complete prevalence, and proportion cured for patients with testicular/paratesticular and extragonadal germ cell cancers in Europe, grouped according to the new list of cancer types developed by RARECARE. We collected data, archived in European cancer registries, with vital status information available to 31st December 2003. We analysed 26,000 cases of testicular, paratesticular and extragonadal germ cell cancers diagnosed 1995–2002, estimating that about 15,600 new testicular/paratesticular and 630 new extragonadal cancer cases occurred per year in EU27, with annual incidence rates of 31.5/1,000,000 and 1.27/1,000,000, respectively. Slightly more than 436,000 persons were alive at the beginning of 2008 with a diagnosis of testicular/paratesticular cancer, and about 17,000 with a diagnosis of extragonadal germ cell cancer. Five-year relative survival was 96% for testicular/paratesticular cancer and 71% for extragonadal germ cell cancer; the proportions cured were 95% and 69%, respectively. We found limited variation in survival between European regions except for non-seminomatous testicular cancer, for which five-year relative survival ranged from 86% in Eastern Europe to 96% in Northern Europe. Survival for all cancer types considered decreased with increasing age at diagnosis. Further investigation is required to establish the real reasons for the lower survival in Eastern Europe. Considering the high prevalence of these highly curable cancers, it is important to monitor patients long-term, so as to quantify treatment-related risks and develop treatments having limited impact on quality of life.